2m 2m 2m 2m 2m 2m 2m
NUVECTIS PHARMA (NVCT)
NASDAQ
$9.24-$0.07 (-0.75%)
Price as of Jun 03, 2026 4:10 PM EDT- $258.6MMarket Cap
- 5.08%1-Year Change
- BiotechnologyIndustry
NUVECTIS PHARMA (NVCT)
$9.24-$0.07 (-0.75%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -18.2M +40.52% | -12.9M -16.01% | -15.4M +16.28% | -13.2M N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Operating Expenses | 9.4M +35.96% | 6.9M -7.82% | 7.5M +25.14% | 6.0M N/A | |
Operating Profit | -27.6M +38.93% | -19.8M -13.32% | -22.9M +19.04% | -19.2M N/A | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Income before Taxes | -28.9M +51.95% | -19.0M -14.65% | -22.3M +16.64% | -19.1M N/A | |
Income Taxes | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -26.4M +39.17% | -19.0M -14.65% | -22.3M +16.64% | -19.1M N/A | |
Net Income from Continuing Operations Applicable to Common | -28.9M +51.95% | -19.0M -14.65% | -22.3M +16.64% | -19.1M N/A | |
Basic EPS and Net Income | -1.32 +18.92% | -1.11 -22.38% | -1.43 -5.30% | -1.51 N/A | |
Diluted EPS and Net Income | -1.32 +18.92% | -1.11 -22.38% | -1.43 -5.30% | -1.51 N/A | |
Basic Weighted Average Shares | 21.8M +27.46% | 17.1M +10.01% | 15.6M +22.90% | 12.7M N/A | |
Diluted Weighted Average Shares | 21.8M +27.46% | 17.1M +10.01% | 15.6M +22.90% | 12.7M N/A | |
Balance Sheet | |||||
Cash and Cash Equivalents | 31.6M +70.69% | 18.5M -3.10% | 19.1M -4.34% | 20.0M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 31.6M +70.69% | 18.5M -3.10% | 19.1M -4.34% | 20.0M N/A | |
Total Current Assets | 31.7M +70.41% | 18.6M -3.01% | 19.2M -5.98% | 20.4M N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Assets | N/A N/A | N/A N/A | N/A N/A | 824,000 N/A | |
Total Assets | 31.7M +70.41% | 18.6M -3.01% | 19.2M -5.98% | 20.4M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 13.3M +49.49% | 8.9M +27.35% | 7.0M +12.90% | 6.2M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | N/A N/A | N/A N/A | N/A N/A | 824,000 N/A | |
Total Liabilities | 13.3M +49.49% | 8.9M +27.35% | 7.0M +12.90% | 6.2M N/A | |
Retained Earnings | -99.7M +36.10% | -73.2M +35.03% | -54.2M +69.60% | -32.0M N/A | |
Total Stockholders Equity | 0 -100.00% | 9.7M -20.39% | 12.2M -14.19% | 14.2M N/A | |
Total Shares Outstanding | 25.7M +31.71% | 19.5M +11.92% | 17.4M +18.96% | 14.6M N/A | |
Cash Flow | |||||
Cash from Operating Activities | -16.0M +30.72% | -12.2M -23.24% | -16.0M +17.66% | -13.6M N/A | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | N/A N/A | 0 N/A | 0 N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 29.1M +149.79% | 11.7M -22.75% | 15.1M -45.75% | 27.8M N/A | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -105.10% +4.53% | -100.55% -10.58% | -112.45% N/A | N/A N/A | |
Return on Equity | -544.47% +213.99% | -173.41% +2.91% | -168.51% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 2.38 +14.00% | 2.09 -23.84% | 2.75 N/A | N/A N/A | |
Cash Ratio | 2.38 +14.18% | 2.08 -23.91% | 2.74 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow